Humanin Peptide Improves Heart Risk Prediction in Dialysis Patients

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in patients undergoing chronic hemodialysis, significantly impacting their quality of life and survival. Despite advancements in medical care, existing risk stratification models often fall short in accurately predicting individual CVD risk within this vulnerable population, leading to suboptimal preventive strategies. There is an urgent need for novel, more precise biomarkers that can enhance prognostic accuracy. This study specifically investigates whether measuring circulating levels of Humanin, a mitochondrial-derived peptide with known cytoprotective properties, can improve the predictive power of current cardiovascular risk assessment tools in chronic hemodialysis patients.